DDX53 and neoplasm: To directly demonstrate the requirement of CD8 + T cells for anticancer responses resulting from the combination treatment, CT26-EphA2 tumor-bearing mice were dually treated with anti-PD-1 and photoimmunotherapy with or without CD8 + T cell depletion.